Vaxart Reports News Data of VXA-CoV2-1 (Oral COVID-19 Vaccine) in P-I Trial Against Other Coronaviruses
Shots:
- The company reported the new data from the P-I COVID-19 trial evaluating the safety & immunogenicity of VXA-CoV2-1 suggesting that vaccine triggers mucosal immunity and includes both the S and the N SARS-Cov-2 proteins and has broad cross-coronavirus activity
- The results showed higher CD8+ T-cell responses as measured by IFN-g and TNF-a induction than the patients vaccinated with Pfizer and Moderna’s vaccines
- The Vaxart vaccine candidate elicited a T-cell response against SARS-Cov-2- as well as showed cross-reactivity against diverse endemic coronaviruses such as 229E- NL63- HKU1- and OC43
Ref: GLOBE NEWSWIRE | Image: Vaxart
Click here to read the full press release
This content piece was prepared by our former Senior Editor. She had expertise in life science research and was an avid reader. For any query reach out to us at connect@pharmashots.com